AR051794A1 - 3-amino-pirazol[3,4b]piridinas como inhibidores de proteintirosinquinasas, su preparacion y uso como medicamento - Google Patents

3-amino-pirazol[3,4b]piridinas como inhibidores de proteintirosinquinasas, su preparacion y uso como medicamento

Info

Publication number
AR051794A1
AR051794A1 ARP050105227A ARP050105227A AR051794A1 AR 051794 A1 AR051794 A1 AR 051794A1 AR P050105227 A ARP050105227 A AR P050105227A AR P050105227 A ARP050105227 A AR P050105227A AR 051794 A1 AR051794 A1 AR 051794A1
Authority
AR
Argentina
Prior art keywords
alkyl
heterocycloalkyl
groups
ring
cycloalkyl
Prior art date
Application number
ARP050105227A
Other languages
English (en)
Inventor
Benjamin Bader
Roman Hillig
Ter Antonius Laak
Arndt Schmitz
Wolfgang Schwede
Dieter Zopf
Hermann Kuenzer
Ursula Moenning
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36580240&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR051794(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of AR051794A1 publication Critical patent/AR051794A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C07D213/85—Nitriles in position 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La utilizacion de los compuestos de la formula general (1) como inhibidores de protein-tirosin quinasas para tratar distintas enfermedades, como aquellas donde participa la angiogénesis, linfangiogénesis o vasculogénesis, vasodilatacion hiperproliferacion de células corporales o enfermedades neurodegenerativas. Reivindicacion 1: Compuestos de la formula general (1), caracterizado porque: R1 representa C1-6-alquilo, C2-6-alquenilo, C2-6-alquinilo, -C3-10-cicloalquilo, C3-10- heterocicloalquilo, arilo o heteroarilo, sustituido opcionalmente con uno o más grupos K iguales o diferentes, donde el C3-10-heterocicloalquilo y/o el heteroarilo está interrumpido por al menos uno de los siguientes átomos en el anillo: nitrogeno, oxígeno y/o azufre, y el C3-10-heterocicloalquilo y/o heteroarilo puede estar unido a la pirazolpiridina solamente a través de un átomo de carbono del anillo, y el C3-10-cicloalquilo y/o el C3-10-heterocicloalquilo puede estar interrumpido por uno o más grupos -(CO)-, -SO- o -SO2- iguales o diferentes en el anillo, y opcionalmente puede contener uno o más enlaces dobles en el anillo, o C3-10-cicloalquilo, arilo, C3-10-heterocicloalquilo o heteroarilo sustituido con el grupo -O-(CH2)n-O-, donde el átomo de oxígeno terminal del grupo -O-(CH2)n-O- está unido directamente a un grupo igual o a un átomo de carbono de un grupo de anillo de C3-10-cicloalquilo, anillo de arilo, anillo de C3-10-heterocicloalquilo o anillo de heteroarilo adjunto; K representa halogeno, hidroxilo o el grupo -OR3, COR4 o -NR5R6, o representa -C3-10-cicloalquilo, C3-10-heterocicloalquilo, arilo o heteroarilo, sustituido opcionalmente con uno o más grupos L iguales o diferentes, donde el C3-10-heterocicloalquilo y/o el heteroarilo está interrumpido por al menos uno de los siguientes átomos en el anillo: nitrogeno, oxígeno y/o azufre, y el C3-10-cicloalquilo y/o el C3-10-heterocicloalquilo puede estar interrumpido opcionalmente en el anillo por uno o más grupos -C(O)-, -SO- o -SO2- iguales o diferentes, y opcionalmente puede contener uno o más enlaces dobles en el anillo; L representa C1-6-alquilo o los grupos -COR4, -OR3 o -NR5R6; R2 representa C1-6-alquilo, C3-10-cicloalquilo, arilo o heteroarilo, sustituido opcionalmente con uno o más grupos M iguales o diferentes; R3 representa C1-6-alquilo, arilo o -(CH2)n-arilo sustituido opcionalmente con uno o más grupos -NR5R6 iguales o diferentes; R4 representa hidrogeno, hidroxilo, C1-6-alquilo o C1- 6-alcoxilo; M representa amino, ciano, halogeno, hidroxilo, nitro o C1-6-alquilo sustituido opcionalmente con uno o más grupos amino, ciano, halogeno, hidroxilo, nitro, C1-6-alcoxilo iguales o diferentes, C2-6-alquenilo, C2-6-alquinilo o los grupos - O-R3, -COR4 o -CO-N-R7; R5 y R6, independientemente uno del otro, representan hidrogeno, C1-6-alquilo o el grupo -COR4; y R7 representa hidrogeno o NH2; n tiene un valor de entre 1 y 4; teniendo en cuenta que cuando: R1 representa metilo, R2 no puede ser simultáneamente metilo, -CH2-O-CH3, fenilo, clorofenilo, benzofuranilo sustituido con hidroxilo y/o metoxilo, -CF3 o furanilo, o cuando R1 representa -CH2-O-CH3, R2 no puede ser simultáneamente metilo, o cuando R1 representa -CH=CH-fenilo, R2 no puede ser simultáneamente fenilo, o cuando R1 representa -CH=CH-clorofenilo, R2 no puede ser simultáneamente fenilo o clorofenilo, o cuando R1 representa -CH=CH-metoxifenilo, R2 no puede ser simultáneamente fenilo o metoxifenilo, o cuando R1 representa fenilo, R2 no puede ser simultáneamente -CF3, metilo, metoxifenilo o fenilo, o cuando R1 representa metoxifenilo, R2 no puede ser simultáneamente -CF3, cuando: R1 representa metilfenilo, R2 no puede ser simultáneamente -CF3, o cuando R1 representa clorofenilo, R2 no puede ser simultáneamente clorofenilo o -CF3, o cuando R1 representa diclorofenilo, R2 no puede ser simultáneamente trimetoxifenilo, o cuando R1 representa bromofenilo, R2 no puede ser simultáneamente trimetoxifenilo, o cuando R1 representa alquilo, alquenilo, arilo, aralquilo, cicloalquilo, un alquilo sustituido con fenilo o p-metoxifenilo, R2 tampoco puede ser simultáneamente alquilo, alquenilo, arilo, aralquilo, ciano, un residuo heterocíclico o cicloalquilo, o cuando R1 representa un radical alquilo inferior, alcoxilo o ariloxilo, R2 no puede ser simultáneamente un radical alquilo inferior, o cuando R1 representa hidroxifenilo, R2 no puede ser simultáneamente heterociclilo o heterocicloalquilo sustituido con -COO-ter-butilo, o cuando R1 representa benciloxifenilo, R2 no puede ser simultáneamente heterocicloalquilo sustituido con -COO-ter-butilo, los solvatos, los hidratos, los estereoisomeros, los diastereomeros, los enantiomeros y las sales de éstos. Reivindicacion 15: Compuestos de las formulas generales (2) y/o (3), caracterizado porque: X representa halogeno u -O-SOz-CmF2m+1; m tiene un valor de entre 1 y 4; y R1a y R2a tienen el mismo significado que el que tienen R1 y R2 de acuerdo con una de las reivindicaciones 1 a 8, donde K puede representar adicionalmente los grupos -COR4 y R3, y también puede representar los grupos trimetilsililo (TMS), ter-butil-dimetilsililo (TBDMS), ter-butil-difenilsililo (TBDPS), trietilsililo (TES), C1-2-alquilo, C3-6-alilo, bencilo o el grupo -COR4a, los solvatos, los hidratos, los estereoisomeros, los diastereomeros, los enantiomeros y las sales de éstos, como intermediarios para la preparacion de compuestos de la formula (1).
ARP050105227A 2004-12-14 2005-12-14 3-amino-pirazol[3,4b]piridinas como inhibidores de proteintirosinquinasas, su preparacion y uso como medicamento AR051794A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102004061288A DE102004061288A1 (de) 2004-12-14 2004-12-14 3-Amino-Pyrazolo[3,4b]pyridine als Inhibitoren von Proteintyrosinkinasen, deren Herstellung und Verwendung als Arzneimittel

Publications (1)

Publication Number Publication Date
AR051794A1 true AR051794A1 (es) 2007-02-07

Family

ID=36580240

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050105227A AR051794A1 (es) 2004-12-14 2005-12-14 3-amino-pirazol[3,4b]piridinas como inhibidores de proteintirosinquinasas, su preparacion y uso como medicamento

Country Status (13)

Country Link
US (1) US7977325B2 (es)
EP (1) EP1846402B1 (es)
JP (1) JP2008523018A (es)
AR (1) AR051794A1 (es)
CA (1) CA2604463C (es)
DE (1) DE102004061288A1 (es)
DO (1) DOP2005000251A (es)
GT (1) GT200500363A (es)
PA (1) PA8656401A1 (es)
PE (1) PE20060737A1 (es)
TW (1) TW200634012A (es)
UY (1) UY29253A1 (es)
WO (1) WO2006063805A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
EP1980561B1 (en) * 2007-03-30 2013-10-09 Nerviano Medical Sciences S.R.L. Substituted 1h-pyrazolo[3,4-b] pyridine derivatives active as kinase inhibitors
NZ584145A (en) 2007-09-14 2012-03-30 Ortho Mcneil Janssen Pharm 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h, 1'h-[1,4'] bipyridinyl-2'-ones
EP2205565B1 (en) 2007-09-14 2013-04-17 Janssen Pharmaceuticals, Inc. 1,3-disubstituted-4-phenyl-1 h-pyridin-2-ones
EA019085B1 (ru) 2007-09-14 2014-01-30 Янссен Фармасьютикалз, Инк. 1',3-двузамещенные 4-(арил-х-фенил)-1н-пиридин-2-оны
NZ585063A (en) * 2007-11-02 2012-05-25 Vertex Pharma [1h- pyrazolo [3, 4-b] pyridine-4-yl] -phenyle or -pyridin-2-yle derivatives as protein kinase c-theta
MX2010005110A (es) 2007-11-14 2010-09-09 Ortho Mcneil Janssen Pharm Derivados de imidazo[1,2-a]piridina y su uso como moduladores alostericos positivos de los receptores de glutamato metabotropico 2.
ES2439291T3 (es) 2008-09-02 2014-01-22 Janssen Pharmaceuticals, Inc. Derivados de 3-azabiciclo[3.1.0]hexilo como moduladores de receptores de glutamato metabotrópicos
US8697689B2 (en) 2008-10-16 2014-04-15 Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
MX2011005242A (es) 2008-11-28 2011-09-06 Ortho Mcneil Janssen Pharm Derivados de indol y benzoxazina como moduladores de los receptores de glutamato metabotropicos.
MY161325A (en) 2009-05-12 2017-04-14 Janssen Pharmaceuticals Inc 1, 2, 4-triazolo[4,3-a]pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CA2760259C (en) 2009-05-12 2018-05-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
US8846673B2 (en) 2009-08-11 2014-09-30 Bristol-Myers Squibb Company Azaindazoles as kinase inhibitors and use thereof
US8742106B2 (en) 2009-12-21 2014-06-03 Novartis Ag Disubstituted heteroaryl-fused pyridines
CN103140490A (zh) 2010-07-15 2013-06-05 百时美施贵宝公司 氮杂吲唑化合物
JP5852664B2 (ja) 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
ES2536433T3 (es) 2010-11-08 2015-05-25 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
CN103298809B (zh) 2010-11-08 2016-08-31 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
FR2970967B1 (fr) * 2011-01-27 2013-02-15 Pf Medicament Derives de type azaindazole ou diazaindazole comme medicament
US10138235B2 (en) 2011-12-14 2018-11-27 Sanofi Pyrazolopyridine derivatives, preparation process therefor and therapeutic use thereof
FR2984325A1 (fr) * 2011-12-14 2013-06-21 Sanofi Sa Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique
EP2689778A1 (en) * 2012-07-27 2014-01-29 Pierre Fabre Medicament Derivatives of azaindoles or diazaindoles for treating pain
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
ME03518B (me) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena
WO2015110435A1 (en) 2014-01-21 2015-07-30 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2160780A1 (de) 1971-12-08 1973-06-14 Basf Ag Pyridino-pyrazole
DE2238400A1 (de) * 1972-08-04 1974-02-14 Hoechst Ag Basische azofarbstoffe, verfahren zu ihrer herstellung und ihre verwendung
DE2355967A1 (de) 1973-11-09 1975-07-24 Hoechst Ag Polycyclische farbstoffe, verfahren zu ihrer herstellung und ihre verwendung
DE2643753A1 (de) * 1976-09-29 1978-04-06 Thomae Gmbh Dr K Neue 1h-pyrazolo eckige klammer auf 3,4-b eckige klammer zu pyridine
DE3001498A1 (de) * 1980-01-17 1981-07-23 Agfa-Gevaert Ag, 5090 Leverkusen Fotografisches material mit einem stabilisierungsmittel, verfahren zu dessen herstellung, ein entwicklungsverfahren, neue pyrazole, ein verfahren zu deren herstellung sowie zwischenprodukte
US5478830A (en) * 1992-05-29 1995-12-26 The Du Pont Merck Pharmaceutical Company Fused-ring heterocycles for the treatment of atherosclerosis
US6046216A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl pyridinone derivatives
CZ2002934A3 (cs) * 1999-09-17 2002-07-17 Abbott Gmbh & Co. Kg Inhibitory kinázy jako terapeutická činidla
EP1308441B1 (en) * 2000-08-11 2009-10-07 Eisai R&D Management Co., Ltd. 2-aminopyridine compounds and use thereof as drugs
JP4272338B2 (ja) * 2000-09-22 2009-06-03 バイエル アクチェンゲゼルシャフト ピリジン誘導体
FR2827603B1 (fr) * 2001-07-18 2003-10-17 Oreal Composes derives de diaminopyrazole substitues par un radical heteroaromatique et leur utilisation en teinture d'oxydation des fibres keratiniques
ATE327673T1 (de) * 2001-08-23 2006-06-15 Bayer Cropscience Sa Substituierte propargylamine

Also Published As

Publication number Publication date
GT200500363A (es) 2006-11-27
EP1846402B1 (de) 2014-02-26
DE102004061288A1 (de) 2006-06-29
US20090030010A1 (en) 2009-01-29
CA2604463C (en) 2014-03-25
DOP2005000251A (es) 2006-06-30
EP1846402A1 (de) 2007-10-24
JP2008523018A (ja) 2008-07-03
US7977325B2 (en) 2011-07-12
WO2006063805A1 (de) 2006-06-22
PE20060737A1 (es) 2006-08-17
PA8656401A1 (es) 2006-07-03
CA2604463A1 (en) 2006-06-22
TW200634012A (en) 2006-10-01
UY29253A1 (es) 2006-06-30

Similar Documents

Publication Publication Date Title
AR051794A1 (es) 3-amino-pirazol[3,4b]piridinas como inhibidores de proteintirosinquinasas, su preparacion y uso como medicamento
AR106755A2 (es) Inhibidores pirrólicos de la proteína quinasa erk, síntesis e intermediarios de los mismos
AR049139A1 (es) Compuestos derivados de benzamidas n - heterociclil - sustituidas como activadores de la glucoquinasa (glk), metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso como medicamento en el tratamiento de la diabetes tipo ii.
PE20030440A1 (es) Fenilsulfonamidas como antagonistas de ccr3
AR064726A1 (es) Inhibidores de rho quinasa
AR054035A1 (es) Derivados benzodioxano y benzodioxolano y uso de los mismos
CY1112533T1 (el) Μεθοδοι και ενωσεις για την παρασκευη αναλογων cc-1065
PE20130012A1 (es) Derivados de pirazol como inhibidores de jak
CA2682329A1 (en) Substituted imidazopyridine derivatives as melanocortin-4 receptor antagonists
PE20061353A1 (es) Compuestos de sulfonamida-tiazolopiridina como activadores de glucocinasa
MY148686A (en) 9-substituted-8-oxoadenine compound
AR047587A1 (es) Moduladores del receptor de histamina-3
WO2007006926A3 (fr) Nouveaux derives de 2,4-dianilinopyrimidines, leur preparation, a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
AR059184A1 (es) Derivados de sulfonamidas, su preparacion y su aplicacion en tarapeutica
AR051334A1 (es) Derivados de 2- amido-4-feniltiazol
DE60236719D1 (de) Purinderivate als antagonisten an purinergen rezeptoren
PE20070212A1 (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen
HRP20070286T3 (en) Substituted diketopiperazines and their use as oxytocyn antagonists
TW200714674A (en) Near-infrared absorbing material and use thereof
TN2010000173A1 (fr) Antagonistes de cgrp
SV2006002126A (es) Derivados de tetrahidroisoquinolilsulfonamidas, su preparacion y su utilizacion en terapeutica
AR047958A1 (es) Derivados de 1-bencil-5-piperazin-1-il-3,4 dihidro-1h-quinazolin-2-ona y sus derivados 1h-benzo(1,2,6)tiadiazina-2,2-dioxidos y 1,4-dihidro-benzo(d)(1,3)oxazinas-2-ona,como moduladores del receptor 5-ht,para el tratamiento de enfermedades del sistema nervioso central.
AR034585A1 (es) Nuevos compuestos de dihidropirimidina ciano substituidos y su uso para tratar padecimientos
EA200101224A1 (ru) Производные пурина, способ их получения и содержащие их фармацевтические композиции
AR040126A1 (es) Compuesto de fenilsulfonilo, composicion farmaceutica que lo comprende y su uso para la elaboracion de un medicamento

Legal Events

Date Code Title Description
FA Abandonment or withdrawal